What does Eptifibatide do?

Eptifibatide is an FDA-approved intravenous antiplatelet peptide marketed as Integrilin. The source describes hospital use in acute coronary syndrome and PCI contexts, where its role is to reduce platelet aggregation involved in clot formation.

How does Eptifibatide work?

The source describes Eptifibatide as a reversible antagonist of platelet glycoprotein IIb/IIIa receptors. By engaging the receptor through a KGD recognition motif, it limits fibrinogen-mediated links between platelets and thereby reduces platelet aggregation. The source also reports a short plasma half-life of about 2.5 hours.

Is Eptifibatide FDA approved?

Yes. The supplied evidence lists Eptifibatide as FDA approved and gives the clinical status as FDA Approved - Acute coronary syndrome and PCI.

What side effects are reported for Eptifibatide?

The source lists bleeding as the most common reported effect, with major bleeding also reported. Other listed concerns include hypotension, thrombocytopenia, allergic reactions, and classification as a high-risk medication by ISMP.

What dose information is available for Eptifibatide?

The source says community dose data are limited and points to research dosing. It also lists FDA-labeling context that includes a 180 mcg/kg IV bolus with IV infusion for up to 72 hours. This is recorded as evidence for review, not as dosing advice.

Other FDA Approved - approved for specific uses

Eptifibatide

Also known as: Integrilin

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

FDA-approved IV antiplatelet peptide marketed as Integrilin.

Status

FDA Approved

Evidence level: human clinical evidence

Typical dose

Limited community data available; see research dosing.

IV bolus and infusion

Researched for

Heart procedure support, clot prevention

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

FDA approved - FDA-approved for specific uses with established human evidence

Use the tools

In plain language

FDA-approved IV antiplatelet marketed as Integrilin.
Described as a synthetic cyclic heptapeptide modeled on barbourin.
Source clinical context includes acute coronary syndrome and PCI.
Community dose information is limited; source points to research or labeling protocols.
Main reported safety concern is bleeding, including major bleeding.

How it's thought to work

Eptifibatide is described as a reversible glycoprotein IIb/IIIa receptor antagonist on platelets. The supplied mechanism evidence links its KGD motif to receptor binding, which interferes with fibrinogen bridging between platelets and reduces aggregation. The source also reports a plasma of roughly 2.5 hours, supporting a comparatively short duration of antiplatelet activity after discontinuation.

What the research shows

Where the research stands

The supplied research summary characterizes Eptifibatide as supported by large randomized human trials. It cites PURSUIT in non-ST-elevation acute coronary syndrome, where death or nonfatal myocardial infarction was lower versus placebo, and ESPRIT in stenting, where the 30-day composite of death, myocardial infarction, or urgent revascularization was reported as about 6.8% with Eptifibatide versus 10.4% with placebo. The same evidence emphasizes bleeding as the principal tradeoff and reports that thrombocytopenia and immunogenicity were not common findings in that summary.

What it shows

✓ Human clinical evidence

FDA-approved for specific uses with established human evidence

△ Limitations

Use only according to approved labeling and qualified medical guidance.

Bottom line: FDA Approved - Acute coronary syndrome and PCI FDA Approved

Typical dosing

CommunityCommunity dataset

Limited community data available

See research protocols

Range: See research dosing

The source reports limited community dose information and points readers to research dosing rather than establishing an independent common-use range.

Research dosing

Indication-specificApproved for specific uses - study doses are indication-specific

Doses observed in studies

180 mcg/kg IV bolus

FDA Approved Labeling - Prescribed dose

Use only according to approved labeling and qualified medical guidance.

Duration: Up to 72 hours
Administration: IV bolus and infusion

Timing & administration

Best time to take

Morning or as directed

Follow recommended protocol

Food recommendation

With or without food

Why this timing?

The source provides only general timing language and a protocol-based frequency note; it does not establish a specific time-of-day rationale for this IV hospital medication.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Bleeding
Major bleeding
Hypotension
Thrombocytopenia
Allergic reactions
High-risk medication per ISMP
FDA approved (Integrilin)

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

deamino-Cys(1)-hArg-Gly-Asp-Trp-Pro-Cys(1)-NH2; Cys1-Cys7 disulfide

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Eptifibatide

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Eptifibatide

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions